{"id":"W2804630302","doi":"10.6000/1929-2279.2018.07.02.3","title":"Pharmacotherapeutic Options for Philadelphia Chromosome-Positive CML","year":2018,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Imatinib; Nilotinib; Dasatinib; Tyrosine kinase; Medicine; Philadelphia chromosome; Cancer research; Bosutinib; Myeloid leukemia; Tyrosine-kinase inhibitor; Oncology; Pharmacology; Internal medicine; Biology; Genetics; Cancer; Chromosomal translocation; Receptor","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002098725,0.0002552957,0.0004214752,0.0008772559,0.0001917969,0.0004489186,0.0003243558,0.0004486071,0.005181681],"category_scores_gemma":[0.0002890002,0.00006122309,0.0003221465,0.000452152,0.0001242099,0.0004700856,0.0002997349,0.001075436,0.001312241],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002225693,"about_ca_system_score_gemma":0.0002925927,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002531465,"about_ca_topic_score_gemma":0.001239262,"domain_scores_codex":[0.9999163,0.00001653569,0.00001190441,0.000009526349,0.00003302957,0.00001263689],"domain_scores_gemma":[0.9999299,0.00002183419,0.00001663299,0.000001877364,0.00001803338,0.00001167623],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001447418,0.0001892481,0.0002937294,0.003022117,0.0000425526,0.0004507746,0.00006646289,0.0001992517,0.005875404,0.002370571,0.02510666,0.9622384],"study_design_scores_gemma":[0.00009644965,0.0004745363,0.002025392,0.001644335,0.0001099663,0.003101305,0.00007056542,0.0001250823,0.001766729,0.001700936,0.9888712,0.000013603],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003389071,0.9817501,0.0006097344,0.002834939,0.00048987,0.00003867557,0.00009535559,0.00003393057,0.01075843],"genre_scores_gemma":[0.01463782,0.9771528,0.00127852,0.001970148,0.0008560319,0.00005630087,0.0002420119,0.000006542395,0.00379984],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005181681,"threshold_uncertainty_score":0.0173344,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1021393409216489,"score_gpt":0.4858416534499229,"score_spread":0.383702312528274,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}